HCPLive Network

Three New Treatments Show Promise for Parkinson's Disease

FRIDAY, March 15 (HealthDay News) -- Three new treatments show promise for patients with Parkinson's disease, according to three studies to be presented at the annual meeting of the American Academy of Neurology, held from March 16 to 23 in San Diego.

Stuart Isaacson, MD, from the University of South Florida, in Tampa, and colleagues randomized 225 patients with Parkinson's disease to receive placebo or droxidopa, an oral pro-drug converted to norepinephrine, for an eight-week treatment period. The researchers found that, at week one, patients receiving droxidopa experienced significant improvement in dizziness/lightheadedness, with a trend toward improvement at week eight. There was a significant improvement in standing systolic blood pressure at week one with droxidopa, and a numerical improvement at week eight.

C. Warren Olanow, MD, from the Mount Sinai School of Medicine, in New York City, and colleagues randomized 337 patients with stable dosages of levodopa to tozadenant (60, 120, 180, or 240 mg twice daily) or placebo. The researchers found that patients in the 120 mg and 180 mg tozadenant groups experienced significant reductions in OFF time at 12 weeks, compared with baseline, with no increase in ON time with troublesome dyskinesia. In a third study, Robert A. Hauser, MD, of the University of South Florida, in Tampa, and colleagues found that, for patients receiving dopamine agonist monotherapy with suboptimal symptom control, treatment with add-on rasagiline resulted in a significant improvement in the Unified Parkinson's Disease Rating Scale (UPDRS) score and in UPDRS-motor scores compared with placebo.

"All of these treatments are promising news for people with Parkinson's disease, which is the second most common neurodegenerative disease after Alzheimer's disease," Hauser said in a statement.

The first, second, and third studies were funded by Chelsea Therapeutics, Biotie Therapies, and Teva Pharmaceuticals, respectively.

Abstract - Isaacson
Abstract - Olanow
Abstract - Hauser
More Information

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
A patient at Texas Health Presbyterian Hospital has tested positive for the deadly virus.
Cannabis users who acknowledge their problem and report withdrawal symptoms are likely to increase abstinence over a 12-month period, according to research published in the Journal of Addiction Medicine.
Omega-3 supplementation can help reduce behavioral issues in adolescents who may be particularly prone to oxytocin receptor gene methylation.
The start of the fall season means that around the country children are settling into their school routines. It also means cold and flu season is just around the corner, and with a particularly harsh winter predicted for parts of the country that could mean bad news for the end of 2014.
Having trainee physicians review cases prior to clinic hours can reduce patient waiting times, flow times, and clinic session times, according to a study published online Sept. 16 in Pain Medicine. The management process studied was first popularized by Toyota in Japan.
Study results show many patients with chronic obstructive pulmonary disease (COPD) may experience cognitive deterioration that becomes more severe as their COPD worsens.
Patients with the relapsing-remitting (RRMS) form of multiple sclerosis (MS) have shown improvement with glatiramer acetate (Copaxone/Teva). But researchers are still uncertain exactly how the drug works. In research published online Sept. 29 in Jama Neurology a University of Texas Southwestern Medical Center team in Dallas, TX, reported on the ways in which glatiramer acetate affects B cells in these patients
More Reading
A patient at Texas Health Presbyterian Hospital has tested positive for the deadly virus.